BET inhibitors function by binding to the bromodomains of BET proteins, thereby preventing them from interacting with acetylated histones. This disrupts the assembly of transcriptional complexes at promoter and enhancer regions of oncogenes. Consequently, the expression of genes critical for tumor growth and survival is downregulated, leading to reduced proliferation and increased apoptosis of cancer cells.